| Similar Articles |
|---|
 |
American Family Physician
February 15, 2006
Luba & Stulberg |
Chronic Plaque Psoriasis Patients and physicians should understand that psoriasis is a chronic disease without a cure, and that it is important to have realistic expectations of treatment. Treatment should focus on improvement, not disappearance, of lesions.   |
Managed Care
June 2003
Thomas Morrow |
The 'Heartbreak of Psoriasis' Has Met Its Match! New therapies that manipulate the immune system offer hope to patients and pose challenges to managed care. |
Managed Care
October 2004
Thomas Morrow |
Evaluating New Therapies for Psoriasis Along with traditional systemic therapies, the American Academy of Dermatology recommends four biologic agents as first-line treatment for psoriasis patients who are candidates for systemic therapy. |
American Family Physician
February 15, 2007
Lucinda M. Buys |
Treatment Options for Atopic Dermatitis Atopic dermatitis is the most common childhood skin disorder in developed countries. Aggressive therapy with emollients is an important intervention for patients with atopic dermatitis. Patients should avoid individual disease triggers and allergens. |
Pharmaceutical Executive
July 1, 2011
Dickmeyer & Rosenbeck |
From Rut to Racetrack Can the pharmaceutical industry deliver on its objective to make cancer a curable, chronic condition? |
The Motley Fool
August 10, 2010
Ryan McBride |
Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive. |
Managed Care
January 2007 |
The Use of Therapeutic Interchange For Biologic Therapies The stated goal of therapeutic interchange is to achieve an improved or neutral outcome with the new agent while reducing overall treatment costs. |
American Family Physician
February 15, 2006 |
Psoriasis: What You Should Know A patient information guide: What is psoriasis... Who gets it and why?... How do I know if I have psoriasis?... How is psoriasis treated?... What can I expect?... |
Nurse Practitioner
April 2009
Randy M. Gordon |
Skin cancer: More than skin deep Skin cancer is the most common carcinoma in the United States, affecting millions. One in five Americans and one in three whites will develop skin cancer in their lifetime. |
AskMen.com
Dustin Driver |
Common Skin Disorders The following skin afflictions are usually embarrassing and sometimes very serious. Thankfully, with a little help from your doctor, they can be treated and managed. |
The Motley Fool
February 10, 2004
David Nierengarten |
The Psoriasis Wars The pharma heavies are battling for the chronic skin disease's market. |
Pharmaceutical Executive
February 1, 2012
Ben Comer |
Best to Market Pharm Exec's Brand of the Year: Abbott's Humira |
The Motley Fool
October 8, 2010
Brian Orelli |
Pfizer's Rash (of Bad News) Is Over Data from Pfizer's phase 2 trial testing tasocitinib against psoriasis, a painful autoimmune skin disease, looks promising even given its small size. |
Pharmaceutical Executive
November 1, 2012
Lauri Mitchell |
Who Pays for Specialty Medicines? Providers and patients fish for that delicate balance between access and abandonment. |
Managed Care
December 2003
David M. Pariser |
Treating Psoriasis Patients With Biologic Agents Improved outcomes with new biologic agents are prompting physicians to integrate them into therapy for psoriasis patients. |
Pharmaceutical Executive
November 1, 2012
Sue Barrowcliffe |
Real World Insights Commercial teams as well as patients can benefit from managed access programs, which are designed to provide access to medicines outside of the clinical and commercial setting, for patients who have no other available treatment options. |
American Family Physician
October 15, 2003 |
Psoriasis What is psoriasis?... Is psoriasis contagious?... How is psoriasis treated?... Will psoriasis go away with treatment? |
Nursing
June 2011
Daniel A. Hussar |
New Drugs 2011: Part 2 In this article, you'll learn about seven recently approved drugs, including: fingolimod hydrochloride, an oral drug indicated to treat patients with relapsing forms of multiple sclerosis. |
Nursing
January 2011
Carl A. Kirton |
HIV: The Changing Epidemic Since its emergence in the early 1980s, HIV infection in the United States has evolved from an acute debilitating condition to a chronic, treatable illness. |
Nurse Practitioner
February 2011
Jennifer M. Belavic |
Annual Drug Update: 2010 in Review In 2010, the FDA approved several new drugs and new indications for use in primary care. From new therapies for adults with rheumatoid arthritis to a combination drug for benign prostatic hyperplasia, NPs need to be aware of the latest medications now available. |
Managed Care
July 2005
Thomas Morrow |
Can CDHPs Resolve Issues Raised by Age of Biologics? While the potential of consumer-directed health plans is promising, this design still leaves many questions about coverage unanswered. |
Pharmaceutical Executive
June 1, 2014
Jill Wechsler |
Compassionate Use Requests Complicate Drug Development Pharma, HCPs, and regulators walk tightrope in addressing early-access push while supporting biomedical R&D. |
Nursing
February 2010
Daniel A. Hussar |
New Drugs 2010, PART 1 In this article, you'll learn about 16 new drugs. |
Nursing
June 2010
Daniel A. Hussar |
New drugs 2010, part 2 In this article, you'll learn about 14 recently marketed new drugs. |
Nursing
March 2012
Daniel A. Hussar |
New Drugs 2012: part I In this article, you'll learn about 11 recently approved drugs. |
The Motley Fool
September 7, 2010
Luke Timmerman |
Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too. |
Pharmaceutical Executive
June 1, 2014
Ben Comer |
Take as Directed: From Force to Finesse in Promoting Adherence Healthcare players tout patient education and engagement as the keys to better drug adherence rates. Patients agree, as long as that translates to convenient and affordable access to therapy. |
Pharmaceutical Executive
January 1, 2013
Al Topin |
The Doctor-Patient Disconnect Doctor-patient conversations aren't always what we think; this basic interaction represents both a problem and an opportunity for today's drug marketers, says the author. |
Fast Company
December 2009
Elizabeth Svoboda |
Biotechs Look Overseas to Launch a Stem-Cell Revolution According to one small biotech, the best way to launch a stem-cell revolution is to do it overseas. |
Pharmaceutical Executive
April 1, 2012 |
Ad Stars The campaigns chosen as this year's Pharm Exec Ad Stars include a diverse mix of clients, health conditions, and media channels. |
CIO
October 29, 2015
Martha Heller |
Amgen uses algorithms to venture into digital healthcare A senior vice president of global marketing and commercial development, says she's working with the CIO to set up a digital healthcare organization that can help physicians better predict how patients will respond to therapies. |
Pharmaceutical Executive
June 1, 2014
O'Connor et al. |
Challenges to the Specialty Business Model New constraints require new solutions. Innovative, value-based pricing models will be critical to securing reimbursement and continued market access of high-price drugs. |
Nursing
February 2009
Daniel A. Hussar |
New Drugs 09: Part 1 Learn about 10 new drugs, including nebivolol HCl, the newest beta-adrenergic blocking agent for hypertension. |
American Family Physician
September 1, 2006 |
Saving Your Skin from Sun Damage The sun's rays, which are called ultraviolet A and ultraviolet B rays (UVA and UVB rays), damage your skin. This leads to early wrinkles, skin cancer, and other skin problems. |
Pharmaceutical Executive
April 1, 2012
Feam & Lagus |
Providing Access Now While regulatory frameworks and medical practices differ between countries, many patients still need early access to new drugs. Industry can help. |
Chemistry World
June 11, 2012
Catherine Bacon |
Which energy saving light bulb is best for sensitive skin? UK researchers have compared the UV emissions given off by different types of energy saving light bulbs so that people with photosensitive skin can reduce their exposure to UV light. |
The Motley Fool
April 8, 2005
David Nierengarten |
The Psoriasis Wars Continue Biogen-Idec hopes its new drug will conquer the lucrative psoriasis market. Investors should consider taking a second look at the company's prospects. |
Chemistry World
March 4, 2011
Elinor Richards |
Laser treatment for late-stage cancer Scientists from China, the US and Peru claim to have successfully treated late-stage breast cancer patients using laser immunotherapy to stimulate patients' own immune systems to fight the cancer. |
HHMI Bulletin
Aug 2011 |
Seeing is Believing Today, researchers are finding clever ways to deliver long-lasting, healthy genes without triggering a serious immune response. |
The Motley Fool
August 10, 2004
Brian Gorman |
Biotech Cost Control Will the high cost of therapies slow sales in the sector? Investors can avoid problems by paying close attention to companies' pipelines and reimbursement trends. |
Chemistry World
May 27, 2015
Phillip Broadwith |
Actavis plan to thwart generics blocked A US court has blocked Ireland-based firm Actavis's attempt to forcibly shift patients onto an extended release version of one of its drugs by withdrawing the original formulation from the market. |
Health
May 2007
Michele Bender |
How to Stay Safe in the Sun Sunscreen fact and fiction. |
